Canagliflozin for advanced kidney disease with MRI study
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests if canagliflozin, a diabetes medication, can help people with very advanced kidney disease or who recently started dialysis. It uses MRI scans to see how the drug affects the heart and kidneys.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced kidney disease (eGFR < 20) or started dialysis in the last 6 months
- You have at least one of: heart muscle thickening, heart failure hospitalization, heart or blood vessel disease in the last year, type 2 diabetes, or high protein in urine
- You do not have type 1 diabetes
- You do not have a history of ketoacidosis (a serious diabetes complication)
- You can undergo an MRI without a pacemaker or certain metal implants
- You are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if canagliflozin, a diabetes medicine, helps remove extra fluid and reduce scarring in people on peritoneal dialysis (home-based dialysis). It may improve your dialysis results and protect your belly lining.
This trial tests canagliflozin to see if it lowers “vascular inflammation” in people with diabetes and stable coronary artery disease. It may help reduce harmful inflammation signals that can raise future heart risk.
This study tests a diabetes medication called canagliflozin in people who receive dialysis treatment for kidney disease. Researchers want to see if it's safe and how it works in patients whose kidneys no longer function on their own.
This study tests whether the drug Henagliflozin can protect the kidneys in people with advanced chronic kidney disease (CKD) who are not yet on dialysis. It may help slow kidney decline and delay the need for dialysis.
This trial tests if empagliflozin, a medicine that helps control blood sugar and protect the kidneys, is safe and effective for people with type 2 diabetes who have very low kidney function (eGFR between 10 and 20). It aims to see if the drug can still benefit the heart and kidneys at this stage.
This study tests whether dapagliflozin can improve kidney and heart-related outcomes in people with severe chronic kidney disease (CKD). You would take the study medicine (or a comparison treatment) and be followed to see how your kidneys and heart do over time.
Hear when a new ESRD, CKD Stage 4, CKD Stage 5 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.